Repligen Corporation
RGEN Healthcare Medical Instruments & Supplies
Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.
Follow RGEN
Repligen Corporation (RGEN) EV/Sales
As of 16 October 2026, Repligen Corporation (RGEN) trades at a EV/Sales of 12.3×. Over the past ten years it has ranged from 7.2× (June 2016) to 34.2× (September 2021); the current reading is higher than 45% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 12.3× | (1.33%) |
| FY2024 | 12.4× | (19.91%) |
| FY2023 | 15.5× | 41.80% |
| FY2022 | 10.9× | (48.74%) |
| FY2021 | 21.4× | (18.70%) |
| FY2020 | 26.3× | 70.23% |
| FY2019 | 15.4× | 29.18% |
| FY2018 | 11.9× | 17.13% |
| FY2017 | 10.2× | 6.71% |
| FY2016 | 9.6× | (6.98%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 9.6× | 12.80% |
| Mar 2026 | 8.5× | (30.91%) |
| Dec 2025 | 12.3× | 17.70% |
| Sep 2025 | 10.4× | 1.99% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BAX Baxter International Inc. compare | 1.8× |
| BLCO Bausch + Lomb Corporation compare | 2.0× |
| AVTR Avantor, Inc. compare | 2.2× |
| ALGN Align Technology, Inc. compare | 2.3× |
| ATR AptarGroup, Inc. compare | 2.3× |
| SOLV Solventum Corporation compare | 2.4× |
| COO The Cooper Companies, Inc. compare | 3.2× |
| TFX Teleflex Incorporated compare | 3.6× |
| RGEN Repligen Corporation | 12.3× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)